last md&a FUTURE OUTLOOK
The Company will continue to need to raise funds for its future operations and for its pre-clinical programs potentially leading to the filing of one or a number of Investigational New Drugs (INDs).
Within the Transcend program, management intends to advance pre-clinical development of the MTF-TZM Herceptin® conjugate program, to advance its Transcendpep family program, to fund further pre-clinical work on its LSD program and evaluation programs and other preclinical programs as initiated by the Company. With sufficient funds, the Company will expand the scope of work on these projects with the intention of creating greater value in its intellectual property and on building stronger licensing partnerships. To assist in commercialization of biOasis’s technology, biOasis engaged Willow Tree Capital Corp. to perform certain business development activities leading to commercial license agreements.
the aforementioned writing doesn't strike me as that of a management team's who feels that a transaction is imminent (def; liable to happen soon). been hearing that for a long - long - looonnngggggg time!
as for the cibc buyer, he may have over paid, but like we've discussed so many times on this forum, share price doesn't matter..... unless you're Jock then its the only thing that matters! booooyyyaaaaaahhhhhhhh!!
#toindwbmahbnDRJ!